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BACKGROUND
Aspirin is a well-established therapy for the secondary prevention of cardiovascular 
events. However, its role in the primary prevention of cardiovascular disease is 
unclear, especially in older persons, who have an increased risk.
METHODS
From 2010 through 2014, we enrolled community-dwelling men and women in 
Australia and the United States who were 70 years of age or older (or ≥65 years of 
age among blacks and Hispanics in the United States) and did not have cardiovas-
cular disease, dementia, or disability. Participants were randomly assigned to re-
ceive 100 mg of enteric-coated aspirin or placebo. The primary end point was a 
composite of death, dementia, or persistent physical disability; results for this end 
point are reported in another article in the Journal. Secondary end points included 
major hemorrhage and cardiovascular disease (defined as fatal coronary heart 
disease, nonfatal myocardial infarction, fatal or nonfatal stroke, or hospitalization 
for heart failure).
RESULTS
Of the 19,114 persons who were enrolled in the trial, 9525 were assigned to receive 
aspirin and 9589 to receive placebo. After a median of 4.7 years of follow-up, the 
rate of cardiovascular disease was 10.7 events per 1000 person-years in the aspirin 
group and 11.3 events per 1000 person-years in the placebo group (hazard ratio, 
0.95; 95% confidence interval [CI], 0.83 to 1.08). The rate of major hemorrhage 
was 8.6 events per 1000 person-years and 6.2 events per 1000 person-years, respec-
tively (hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P<0.001).
CONCLUSIONS
The use of low-dose aspirin as a primary prevention strategy in older adults re-
sulted in a significantly higher risk of major hemorrhage and did not result in a 
significantly lower risk of cardiovascular disease than placebo. (Funded by the 
National Institute on Aging and others; ASPREE ClinicalTrials.gov number, 
NCT01038583.)
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Dramatic increases in life expec-tancy over the past century have led to a substantial demographic shift toward an 
aging society in many countries. Thus, maintain-
ing good health in older persons is an increas-
ingly important public health aim. Cardiovascu-
lar diseases are among the principal causes of 
disability and death in older persons, and there-
fore, preventive interventions for such diseases 
are a high priority.1-3
Low-dose aspirin is among the most widely 
used agents for the prevention of cardiovascular 
disease.4-8 Its efficacy has been established in 
secondary prevention trials, in which the bene-
fits associated with reducing the rates of both 
myocardial infarction and ischemic stroke have 
appeared to outweigh the risk of hemorrhage.9,10 
In primary prevention trials, involving partici-
pants in whom the risk of cardiovascular disease 
was typically lower than the risk seen in second-
ary prevention trials, the risks and benefits of 
low-dose aspirin have been more finely balanced. 
The role of low-dose aspirin as a primary pre-
vention strategy is debated.11-13
In elderly populations, the risk of cardiovas-
cular disease is higher and the potential benefits 
of aspirin may accordingly be greater than in 
younger populations. However, an increased risk 
of bleeding has also been observed in the elderly 
age group.10,14-17 Because a limited number of 
older persons have been included in previous pri-
mary prevention trials, the risk–benefit balance 
in this age group is unknown.18
In the primary analysis of the Aspirin in Re-
ducing Events in the Elderly (ASPREE) trial, now 
published in the Journal,19,20 we report that daily 
use of low-dose aspirin did not prolong disability-
free survival among the elderly. Here, we report 
findings from the ASPREE trial regarding the 
effect of aspirin on the prespecified secondary 
end points of cardiovascular disease and major 
hemorrhage. We also present analyses of the 
nonprespecified end point of major adverse car-
diovascular events.
Me thods
Trial Design
Details of the trial rationale and design have 
been reported previously.21-23 The protocol and 
statistical analysis plan are available with the 
full text of this article at NEJM.org. In brief, we 
conducted this randomized, double-blind, placebo-
controlled clinical trial to evaluate the effect of 
daily use of 100 mg of enteric-coated aspirin in 
community-dwelling older adults.
Bayer Pharma (Germany) provided the trial 
drug (aspirin) and placebo but had no other role 
in the trial. The Department of Epidemiology 
and Preventive Medicine at Monash University in 
Australia coordinated the data collection and 
was responsible for statistical analyses. Coordi-
nation of the trial and monitoring of sites was 
conducted by this department in Australia and 
by the Berman Center for Outcomes and Clinical 
Research in the United States.
The trial was approved by the ethics commit-
tee at each participating center, and all the par-
ticipants provided written informed consent be-
fore enrollment. The trial funder (the National 
Institute on Aging) and an independent data and 
safety monitoring board, whose members had 
been appointed by the National Institute on Ag-
ing, reviewed reports on the accumulating data 
at regular intervals. Trial centers were randomly 
audited; a data-quality committee monitored for 
the completeness and accuracy of the data, and the 
independent data and safety monitoring board 
monitored for safety. All the authors vouch for 
the accuracy and completeness of the data and 
analyses and for the fidelity of the trial to the 
protocol.
Trial Participants
Eligible participants were community-dwelling 
adults from Australia and the United States who 
were 70 years of age or older (or ≥65 years of age 
among blacks and Hispanics in the United 
States). Eligibility criteria are provided in Table 
S1 in the Supplementary Appendix, available at 
NEJM.org. Participants were required to be free 
from overt coronary heart disease, overt cerebro-
vascular disease, atrial fibrillation, a clinical diag-
nosis of dementia, clinically significant physical 
disability, a high risk of bleeding, anemia, and a 
known contraindication to or inability to take 
aspirin. Key exclusion criteria were the current 
regular use of an anticoagulant or antiplatelet 
medication other than aspirin, a systolic blood 
pressure of 180 mm Hg or more or a diastolic 
blood pressure of 105 mm Hg or more, a medi-
cal indication for or contraindication to regular 
aspirin therapy, or the presence of a condition 
that, in the opinion of the primary care physician, 
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was likely to result in death within 5 years. Par-
ticipants were allowed to take other nonsteroidal 
antiinflammatory drugs (NSAIDs), with the rec-
ommendation to take the lowest dose for the 
shortest duration necessary.
Trial Procedures
Participants who had a rate of adherence to pill 
ingestion, as assessed by pill count, of 80% or 
greater during a 1-month placebo run-in phase 
were randomly assigned, in a 1:1 ratio, to receive 
aspirin or placebo. Randomization was stratified 
according to trial center and age (65 to 79 years or 
≥80 years). Annual in-person visits and medical-
record reviews were supplemented by regular 
telephone calls to encourage retention in the 
trial and facilitate the collection of clinical data 
(Table S2 in the Supplementary Appendix).
Trial participants, investigators, and general 
practitioner associate investigators were unaware 
of the trial-group assignments until the publica-
tion of this article. Adherence to the trial inter-
vention was assessed annually by means of tablet 
counts on returned bottles of aspirin or placebo.
Committees whose members were unaware 
of the trial-group assignments were responsible 
for adjudication of all potential clinical end-point 
events. Descriptions of the definitions and pro-
cesses used for adjudication are provided in the 
Supplementary Appendix. Additional information 
regarding the adjudication of major hemorrhagic 
events has been published previously.24 Data on 
causes of death are provided in a separate article 
in the Journal.20
Cardiovascular Events
A prespecified secondary end point of the trial 
was cardiovascular disease, which was a com-
posite of fatal coronary heart disease, nonfatal 
myocardial infarction, fatal or nonfatal stroke, 
or hospitalization for heart failure. The individual 
components of this end point were not pre-
specified as separate end points but were evalu-
ated in a post hoc analysis to assist in the inter-
pretation of the composite end point.
Fatal coronary heart disease was defined as 
death from myocardial infarction, sudden car-
diac death, or any other death in which the un-
derlying cause was considered to be coronary 
heart disease. Fatal stroke was defined as any 
death in which the underlying cause was an ob-
struction or rupture in the intracranial or extra-
cranial cerebral arterial system. Fatal cardiovas-
cular disease was defined as any death in which 
the underlying cause was coronary heart disease 
or stroke.
The definition of nonfatal myocardial infarc-
tion was based on joint guidelines of the Euro-
pean Society of Cardiology and the American 
College of Cardiology.25 Hospitalization for heart 
failure was defined as any unplanned stay, over-
night or longer, in a hospital environment (emer-
gency department, observation unit, or inpatient-
care unit) or a similar facility, for which the 
principal reason for admission was heart failure. 
The definition of nonfatal stroke was based on 
the World Health Organization definition of rap-
idly developing clinical signs of focal or global 
disturbance of cerebral function lasting more 
than 24 hours (unless interrupted by surgery or 
death), with no apparent cause other than ische-
mic or hemorrhagic cerebrovascular disease.26 In 
both Australia and the United States, source docu-
mentation — including clinical notes, hospital-
ization records, and imaging studies (computed 
tomographic scans or magnetic resonance im-
ages) — was requested for events that were 
thought to be potential end-point events.
The nonprespecified end point of major ad-
verse cardiovascular events was a composite of 
fatal coronary heart disease (excluding death 
from heart failure), nonfatal myocardial infarc-
tion, or fatal or nonfatal ischemic stroke. This end 
point included the conditions related to ischemia 
and thrombosis that are most likely to be affected 
favorably by low-dose aspirin.
Major Hemorrhagic Events
Another prespecified secondary end point was 
major hemorrhage, which was a composite of 
hemorrhagic stroke, symptomatic intracranial 
bleeding, or clinically significant extracranial 
bleeding. Clinically significant extracranial bleed-
ing was defined as bleeding that led to transfu-
sion, hospitalization, prolongation of hospital-
ization, surgery, or death.
Statistical Analysis
In intention-to-treat analyses, Cox proportional-
hazards models were used to compare the aspi-
rin group with the placebo group with regard to 
time-to-event end points. Cause-specific hazards 
were compared between groups, with deaths 
from causes other than those included in the end 
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point of interest treated as censoring events. Con-
fidence intervals were not adjusted for multiple 
comparisons, and P values are not presented for 
secondary or nonprespecified end points, except 
for major hemorrhage as a safety end point. 
Proportional-hazards assumptions were tested as 
a null hypothesis of a zero slope in a regression 
model of scaled Schoenfeld residuals against 
time; all P values were found to be greater than 
0.1, indicating satisfaction of the assumption for 
all end points. Cumulative incidences were used to 
show event risk. The cumulative incidences were 
based on competing-risks regression models, 
which were stratified according to trial group 
and which allowed for the competing risk of 
death from causes other than those included in 
the end point of interest.27
Subgroups of potential relevance to the risk 
of cardiovascular disease that were specified in 
the statistical analysis plan included sex, age 
(younger than the median age vs. the median age 
or older), country of residence (Australia vs. the 
United States), race or ethnic group (white in 
Australia, white in the United States, black, His-
panic, or other), smoking (never smoked, former 
smoker, or current smoker), body-mass index 
(the weight in kilograms divided by the square of 
the height in meters; <20 [underweight], 20 to 24 
[normal weight], 25 to 29 [overweight], or ≥30 
[obese]), previous regular use of aspirin (yes vs. 
no), and the presence of diabetes, hypertension, 
and dyslipidemia at baseline (yes vs. no, for each 
condition).23 Nonprespecified subgroups that 
were also considered to be of interest included 
the number of cardiovascular risk factors (diabe-
tes, hypertension, dyslipidemia, and current or 
former smoking) that were present (0 or 1, 2, or 
3 or 4), the presence of chronic kidney disease 
(yes vs. no), and the use of statins or NSAIDs at 
randomization (yes vs. no, for each type of drug). 
A nonprespecified subgroup of potential rele-
vance to the risk of major hemorrhage was the 
use of proton-pump inhibitors at randomization 
(yes vs. no). Interaction terms in Cox proportional-
hazards models were used to test for heteroge-
neity of effect between subgroups.
R esult s
Participants and Follow-up
From March 2010 through December 2014, a 
total of 19,114 persons were enrolled in the trial 
and underwent randomization (9525 participants 
to the aspirin group and 9589 to the placebo 
group) (Fig. S1 in the Supplementary Appendix). 
The trial participants had a median age of 74 
years at randomization, and 56% were women 
(Table 1). A total of 87% were Australian residents 
and 13% were U.S. residents. The two trial 
groups had similar cardiovascular risk profiles. 
At trial entry, one third of the participants re-
ported use of statins and 14% reported regular 
use of NSAIDs.
The intervention phase ceased on June 12, 
2017. All analyses were restricted to events that 
occurred through that date. The median follow-
up was 4.7 years; 1.5% of the participants in the 
aspirin group and 1.6% of those in the placebo 
group had been lost to follow-up by the end of 
the trial, and 1.2% of the participants in each 
group had withdrawn consent (Fig. S1 in the 
Supplementary Appendix). In the final 12 months 
of the trial, 62% of the participants in the aspi-
rin group and 64% of those in the placebo group 
were still taking the assigned trial intervention.
Cardiovascular Events
Rates of cardiovascular events are shown in Ta-
ble 2 and Figure 1, and further details, including 
data on subclassification of the events, are pro-
vided in Table S3 in the Supplementary Appen-
dix. The rate of the prespecified secondary end 
point of cardiovascular disease did not differ 
significantly between the aspirin group and the 
placebo group (10.7 events per 1000 person-years 
of follow-up and 11.3 events per 1000 person-
years, respectively; hazard ratio, 0.95; 95% con-
fidence interval [CI], 0.83 to 1.08).
The rate of major adverse cardiovascular 
events was 7.8 events per 1000 person-years in 
the aspirin group and 8.8 events per 1000 person-
years in the placebo group (hazard ratio, 0.89; 
95% CI, 0.77 to 1.03) (Table 2, and Fig. S2 in 
the Supplementary Appendix). Individual rates 
of myocardial infarction, ischemic stroke, fatal 
cardiovascular disease, and hospitalization for 
heart failure were similar in the two groups 
(Table 2, and Figs. S3 and S4 in the Supplemen-
tary Appendix).
There was no evidence of a differential effect 
of aspirin on the risk of cardiovascular disease 
in any analyses of the prespecified subgroups or 
in post hoc analyses of subgroups of potential 
relevance to the risk of cardiovascular disease 
(Figs. S5 and S6 in the Supplementary Appendix). 
There was also no evidence of an interaction 
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between trial group and any of the subgroups 
with regard to the end point of major adverse 
cardiovascular events (Figs. S7 and S8 in the 
Supplementary Appendix).
Major Hemorrhagic Events
Rates of major hemorrhagic events are shown 
in Table 3, cumulative incidences are shown in 
Figure 2, and further details, including data on 
subclassification of the events, are provided in 
Table S4 in the Supplementary Appendix. The rate 
of major hemorrhage was 8.6 events per 1000 
person-years in the aspirin group, as compared 
with 6.2 events per 1000 person-years in the 
placebo group (hazard ratio, 1.38; 95% CI, 1.18 
to 1.62; P<0.001). The progressive increase in the 
cumulative incidence of major hemorrhage across 
the trial follow-up period indicates that the risk 
of bleeding persisted throughout the course of 
therapy (Fig. 2). The rate of fatal hemorrhage 
was less than 1 event per 1000 person-years in 
each group.
Gastrointestinal bleeding accounted for just 
less than half the major hemorrhagic events. The 
higher risk of upper gastrointestinal bleeding 
with aspirin than with placebo was particularly 
pronounced (hazard ratio, 1.87; 95% CI, 1.32 to 
2.66) (Table 3). The risk of intracranial bleeding 
was also higher with aspirin than with placebo 
(hazard ratio, 1.50; 95% CI, 1.11 to 2.02) (Fig. S9 
in the Supplementary Appendix), and this find-
ing was reflected across all subtypes of intracra-
nial bleeding (Table 3). There was no evidence 
of a differential effect of aspirin on the risk of 
bleeding in any subgroup analysis, except for the 
possibility of a less harmful effect with increas-
ing age (Figs. S10 and S11 in the Supplementary 
Appendix).
Discussion
The ASPREE trial showed that, among elderly 
participants, the use of low-dose aspirin did not 
result in a significantly lower rate of the primary 
end point of disability-free survival (a composite 
that integrated the risks and benefits of aspirin) 
than placebo after a median follow-up of 4.7 
years.19 On the basis of the results of previous 
trials, it was anticipated that benefits of aspirin 
treatment might arise from a reduction in the 
rate of cardiovascular events.28-35 However, in this 
trial, the rate of the prespecified secondary end 
point of cardiovascular disease (a composite that 
Variable
Aspirin 
(N = 9525)
Placebo 
(N = 9589)
no. (%)
Male sex 4152 (44) 4179 (44)
Age ≥74 yr 4806 (50) 4766 (50)
Black race† 451 (5) 450 (5)
Obese‡ 2820 (30) 2857 (30)
Smoking
Current 352 (4) 383 (4)
Former 3909 (41) 3890 (41)
Never 5264 (55) 5316 (55)
Diabetes§ 1027 (11) 1030 (11)
Hypertension¶ 7065 (74) 7148 (75)
Dyslipidemia‖ 6159 (65) 6308 (66)
Chronic kidney disease** 2456 (26) 2464 (26)
Number of cardiovascular risk factors††
0 or 1 2935 (31) 2885 (30)
2 3968 (42) 4049 (42)
3 or 4 2622 (28) 2655 (28)
Previous regular aspirin use‡‡ 1053 (11) 1041 (11)
Statin use at trial entry§§ 3244 (34) 3226 (34)
Use of nonsteroidal antiinflammatory drug  
at trial entry
1371 (14) 1342 (14)
Use of H2-receptor blocker at trial entry 189 (2) 183 (2)
Use of proton-pump inhibitor at trial entry 2340 (25) 2374 (25)
*  For all variables, odds ratios were between 0.67 and 1.50 (with an odds ratio 
of 1.50 as the prespecified limit for performing an adjusted analysis of end 
points) and there were no significant (P>0.05) differences between the two 
trial groups.
†  Data on race were reported by the participants.
‡  Obese was defined as a body-mass index (the weight in kilograms divided 
by the square of the height in meters) of 30 or higher. Data were available 
for 19,035 participants; data on height, weight, or both were missing for 40 
participants in the aspirin group and 39 in the placebo group.
§  The presence of diabetes was based on participants’ report of diabetes mel-
litus or a fasting glucose level of at least 126 mg per deciliter (≥7 mmol per 
liter) or receipt of treatment for diabetes.
¶  Hypertension was defined as treatment for high blood pressure or a blood 
pressure of more than 140/90 mm Hg at trial entry.
‖  Dyslipidemia was defined as the receipt of cholesterol-lowering medication 
or as a serum cholesterol level of at least 212 mg per deciliter (≥5.5 mmol 
per liter) in Australia and at least 240 mg per deciliter (≥6.2 mmol per liter) 
in the United States or as a low-density lipoprotein level of more than 160 mg 
per deciliter (>4.1 mmol per liter).
**  Chronic kidney disease was defined as an estimated glomerular filtration rate 
of less than 60 ml per minute per 1.73 m2 or a ratio of albumin (in milligrams 
per liter) to creatinine (in millimoles per liter) in urine of 3 or more.
††  Cardiovascular risk factors were diabetes, hypertension, dyslipidemia, and 
current or former smoking.
‡‡  Data were available for 19,112 participants; data were missing for 2 partici-
pants in the placebo group.
§§  Data for statin use included 483 participants (247 in the aspirin group and 
236 in the placebo group) who were taking nonstatin lipid-lowering therapies.
Table 1. Demographic Characteristics, Cardiovascular Risk Factors,  
and Treatment of the Participants at Randomization.*
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accounted for all cardiovascular events, includ-
ing stroke due to intracranial hemorrhage and 
hospital admission for cardiac failure) was not 
significantly lower with low-dose aspirin than 
with placebo. The hazard ratio for this end point 
was 0.95 (95% CI, 0.83 to 1.08), which rules out 
the possibility of a major protective effect of 
aspirin but is compatible with a more modest 
lowering of risk of up to 17%. The rates of fatal 
cardiovascular disease and hospitalization for 
heart failure were similar in the two trial groups.
We also examined a nonprespecified end point 
of major adverse cardiovascular events, which 
was defined as a composite of fatal coronary 
heart disease, nonfatal myocardial infarction, or 
fatal or nonfatal ischemic stroke. This end point 
included the cardiovascular events that are most 
likely to be influenced favorably by aspirin. The 
rate of major adverse cardiovascular events did 
not differ significantly between the two groups. 
A similar conclusion was reached with regard to 
the individual rates of myocardial infarction and 
ischemic stroke.
Interpretation of these results should take into 
account the lower-than-expected rate of cardio-
End Point
Overall 
(N = 19,114)
Aspirin 
(N = 9525)
Placebo 
(N = 9589)
Hazard Ratio 
(95% CI)
no. of  
participants  
with event
no. of  
participants  
with event
rate per  
1000 person-yr
no. of  
participants  
with event
rate per  
1000 person-yr
Cardiovascular disease† 922 448 10.7 474 11.3 0.95 (0.83–1.08)
Major adverse cardiovascular event‡ 701 329 7.8 372 8.8 0.89 (0.77–1.03)
Fatal cardiovascular disease§ 159 78 1.8 81 1.9 0.97 (0.71–1.33)
Hospitalization for heart failure 171 88 2.1 83 1.9 1.07 (0.79–1.44)
Fatal or nonfatal myocardial infarction 355 171 4.0 184 4.3 0.93 (0.76–1.15)
Fatal or nonfatal ischemic stroke¶ 315 148 3.5 167 3.9 0.89 (0.71–1.11)
*  Because some end points were composites, a participant who had events for more than one component of the composite (e.g., stroke and 
then acute myocardial infarction) would contribute only the first event that occurred to the composite end point but would contribute an 
event to the separate analyses of each component. Hence, summation of the number of events for separate components of a composite 
end point does not equate to the number of events for the composite end point. The confidence intervals shown in this table have not been 
adjusted for multiple comparisons, and inferences drawn from them may not be reproducible.
†  Cardiovascular disease, a prespecified secondary end point, was a composite of fatal coronary heart disease (death from myocardial infarc-
tion, sudden cardiac death, or any other death in which the underlying cause was considered to be coronary heart disease), nonfatal myo-
cardial infarction, fatal or nonfatal stroke (including hemorrhagic stroke), or hospitalization for heart failure.
‡  Major adverse cardiovascular events, a nonprespecified end point, was a composite of fatal coronary heart disease (excluding death from 
heart failure), nonfatal myocardial infarction, or fatal or nonfatal ischemic stroke.
§  Fatal cardiovascular disease was defined as any death from stroke (including hemorrhagic stroke) or coronary heart disease.
¶  Data for ischemic stroke included cases that were adjudicated as ischemic stroke, cases for which stroke type was uncertain after adjudica-
tion, and cases of ischemic stroke with hemorrhagic transformation.
Table 2. Cardiovascular Events.*
Figure 1. Cumulative Incidence of Cardiovascular Disease.
Shown is the incidence of the prespecified secondary end point of cardio-
vascular disease (a composite of fatal coronary heart disease, nonfatal 
myocardial infarction, fatal or nonfatal stroke, or hospitalization for heart 
failure) according to trial group. The graph stops at year 6 because only a 
small number of participants (44 in the aspirin group and 43 in the placebo 
group) reached year 7. The inset shows the same data on an enlarged y axis.
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vascular disease among the trial participants. In 
the trial protocol, the anticipated rate was 22.4 
events per 1000 person-years. The observed rate 
was approximately half this estimate, most likely 
reflecting the relatively good health of the par-
ticipant population at recruitment and the de-
clining rate of cardiovascular disease in the two 
countries over time and across all age groups.36-39 
Because of these factors, the absolute benefit 
that results from any proportionally lower rate of 
cardiovascular disease may be less than the ben-
efit observed in studies from previous decades 
and is less likely than it had been to outweigh 
the risk of adverse events from aspirin.
This trial also showed that the risk of major 
hemorrhage was significantly higher with aspi-
rin than with placebo. Major hemorrhagic events 
primarily involved upper gastrointestinal and 
intracranial bleeding. The relative effect of aspi-
rin use, as compared with placebo, on the risk 
of major hemorrhage was constant over time, 
suggesting that persons who receive low-dose 
aspirin have a risk of bleeding that does not 
decline with continued use.
These two results — the absence of a large 
benefit on cardiovascular disease coupled with 
the higher risk of bleeding with the use of low-
dose aspirin — are compatible with the results 
of a recent meta-analysis of eight primary pre-
vention trials, predominantly involving adults 
younger than 70 years of age, which showed a 
17% lower risk of nonfatal myocardial infarction 
and a 14% lower risk of stroke, coupled with a 
higher risk of serious bleeding, among partici-
pants who received aspirin than among those in 
control groups.33,40-47 As would be expected, the 
End Point
Overall 
(N = 19,114)
Aspirin 
(N = 9525)
Placebo 
(N = 9589)
Hazard Ratio 
(95% CI) P Value
no. of  
participants  
with event
no. of  
participants  
with event
rate per  
1000 person-yr
no. of  
participants  
with event
rate per  
1000 person-yr
Major hemorrhage† 626 361 8.6 265 6.2 1.38 (1.18–1.62) <0.001
Intracranial bleeding
Any 179 107 2.5 72 1.7 1.50 (1.11–2.02) —
Hemorrhagic stroke 77 43 1.0 34 0.8 1.27 (0.81–2.00) —
Subdural or extradural hemorrhage 61 39 0.9 22 0.5 1.79 (1.06–3.02) —
Subarachnoid hemorrhage‡ 32 18 0.4 14 0.3 1.30 (0.64–2.60) —
Extracranial bleeding
Upper gastrointestinal bleeding 137 89 2.1 48 1.1 1.87 (1.32–2.66) —
Lower gastrointestinal bleeding 127 73 1.7 54 1.3 1.36 (0.96–1.94) —
Bleeding at another site§ 189 101 2.4 88 2.1 1.16 (0.87–1.54) —
Fatal bleeding
Fatal major hemorrhage¶ 52 28 0.7 24 0.6 1.18 (0.68–2.03) —
Fatal hemorrhagic stroke 26 13 0.3 13 0.3 1.01 (0.47–2.17) —
*  Because some end points were composites, a participant who had events for more than one component of the composite (e.g., stroke and 
then acute myocardial infarction) would contribute only the first event that occurred to the composite end point but would contribute an 
event to the separate analyses of each component. Hence, summation of the number of events for separate components of a composite 
end point does not equate to the number of events for the composite end point. The confidence intervals shown in this table have not been 
adjusted for multiple comparisons, and inferences drawn from them may not be reproducible.
†  Major hemorrhage, a prespecified secondary end point, was a composite of hemorrhagic stroke, symptomatic intracranial bleeding, or extra-
cranial bleeding that led to transfusion, hospitalization, prolonged hospitalization, surgery, or death.
‡  Data for subarachnoid hemorrhage included 18 persons who had subarachnoid hemorrhage and 14 who had a subarachnoid hemorrhagic 
stroke.
§  Bleeding at another site included hematuria, bleeding at a surgical site, bleeding after trauma, and epistaxis.
¶  Data for fatal major hemorrhage included deaths that were adjudicated to be from major hemorrhage.
Table 3. Major Hemorrhagic Events.*
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incidence of bleeding in this trial was substan-
tially higher than the incidence in trials with 
younger participants.16,17,34 Because this trial en-
rolled healthy older persons from the general 
population, the results are likely to be broadly 
applicable to the healthy elderly, who are typi-
cally considered for primary prevention of car-
diovascular disease. In contrast with most previ-
ous primary prevention trials, this trial did not 
enroll participants on the basis of elevated car-
diovascular risk.
Current guidelines in the United States, Europe, 
and Australia have noted that there is limited 
evidence regarding the use of aspirin for pri-
mary prevention of cardiovascular disease in the 
elderly.48-50 Nevertheless, many millions of rela-
tively healthy older persons in the United States 
and Australia take low-dose aspirin with the 
assumption that it will reduce the likelihood of 
future cardiovascular disease and stroke. Inter-
pretation of the results of this trial should take 
into account the low percentage of participants 
(11%) who had been regularly taking low-dose 
aspirin before entering the trial. The trial did not 
directly address the question of whether healthy 
older persons who have been taking aspirin for 
primary prevention should continue its use.
This trial has some limitations. First, by the 
end of the trial, only approximately two thirds of 
the participants were still taking the assigned 
trial intervention, and this adherence rate may 
have led to an underestimation of any benefit of 
aspirin on cardiovascular outcomes. However, 
the adherence rate was sufficiently high for an 
increased bleeding risk to be identified, and the 
rate was probably similar to that seen in clinical 
practice.51,52 Second, the end point of major ad-
verse cardiovascular events is commonly used in 
trials of antithrombotic therapy but was not pre-
specified in this trial. However, the results for 
this end point were similar to those for the pre-
specified end point that included hemorrhagic 
stroke and hospitalization for heart failure.
In conclusion, in this randomized trial involv-
ing healthy elderly persons who did not have 
known cardiovascular disease, the use of low-
dose aspirin resulted in a significantly higher 
risk of major hemorrhage and did not result in a 
significantly lower risk of cardiovascular disease 
than placebo.
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